MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

DownloadDownload image
In-process research anddevelopment, net of...$72,826,562 Inventory$22,639,342 Cash and cashequivalents$7,295,451 Accounts receivable, netof allowances$4,049,111 Prepaid expenses$3,162,940 Total other assets$72,826,562 Total current assets$37,146,844 Total assets$109,973,406 Total liabilities andstockholders equity$109,973,406 Total stockholdersequity$58,413,701 Total liabilities$51,559,705 Accumulated deficit-$69,574,025 Additional paid-in capital$127,979,246 Total currentliabilities$44,710,394 Note payable torelated party-Related...$3,800,111 Deferred tax liability$3,049,200 Common stock - 0.0001par value...$8,480 License payable$18,250,000 Due to relatedparty-Related Party$11,494,578 Accounts payable$10,446,900 Accrued expenses$4,518,916
Balance Sheet
source: myfinsight.com

CITIUS ONCOLOGY, INC. (CTOR)

CITIUS ONCOLOGY, INC. (CTOR)